+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent



Development of SU5416, a selective small molecule inhibitor of VEGF receptor tyrosine kinase activity, as an anti-angiogenesis agent



Anti-Cancer Drug Design 15(1): 29-41



Angiogenesis, or the sprouting of new blood vessels, is a central process in the growth of solid tumors. For many cancers, the extent of vascularization of a tumor is a negative prognostic indicator signifying aggressive disease and increased potential for metastasis. Recent efforts to understand the molecular basis of tumor-associated angiogenesis have identified several potential therapeutic targets, including the receptor tyrosine kinases for the angiogenic factor vascular endothelial growth factor (VEGF). Here we review the approach taken at SUGEN, Inc. to discover and develop small molecule inhibitors of receptor tyrosine kinases as anti-angiogenic agents. We focus on SU-5416, a selective inhibitor of VEGF receptors that is currently in clinical development for the treatment of advanced malignancies. Its biochemical, biological and pharmacological properties are reviewed and clinical implications discussed.

Please choose payment method:






(PDF emailed within 1 workday: $29.90)

Accession: 010446945

Download citation: RISBibTeXText

PMID: 10888034


Related references

Combining a selective VEGF receptor inhibitor and a selective PDGF receptor inhibitor recapitulates the anti-tumor efficacy of SU11248, a selective oral multi-targeted tyrosine kinase inhibitor with anti-tumor and anti-angiogenic activity through targeting PDGFR, VEGFR, KIT and FLT3. Proceedings of the American Association for Cancer Research Annual Meeting 44: 970, 2003

SU5416, a small molecule tyrosine kinase receptor inhibitor, has biologic activity in patients with refractory acute myeloid leukemia or myelodysplastic syndromes. Blood 102(3): 795-801, 2003

Phase II clinical-laboratory of the anti-angiogenesis receptor tyrosine kinase inhibitor, SU5416 in refractory acute myelogenous leukemia and myelodysplasia. Blood 98(11 Part 1): 118a, 2001

Antitumor effects of ZD6474, a small molecule VEGF receptor tyrosine kinase inhibitor that is also active against EGF receptor tyrosine kinase. Proceedings of the American Association for Cancer Research Annual Meeting 43: 1080-1081, 2002

SU5416, a small molecule VEGF receptor inhibitor, exhibits durable inhibition of VEGF-dependent phosphorylation of Flk-1/KDR in cells. Proceedings of the American Association for Cancer Research Annual Meeting (41): 446-447, 2000

Effects of SU5416, a small molecule tyrosine kinase receptor inhibitor, on FLT3 expression and phosphorylation in patients with refractory acute myeloid leukemia. Leukemia Research 28(7): 679-689, 2004

Administration of VEGF receptor tyrosine kinase inhibitor increases VEGF production causing angiogenesis in human small-cell lung cancer xenografts. International Journal of Oncology 33(3): 525-532, 2008

Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma. Clinical Cancer Research 10(1 Pt 1): 88-95, 2004

Phase II study of SU5416--a small-molecule, vascular endothelial growth factor tyrosine-kinase receptor inhibitor--in patients with refractory myeloproliferative diseases. Cancer 97(8): 1920-1928, 2003

PTK787/ZK 222584, a small molecule tyrosine kinase receptor inhibitor of vascular endothelial growth factor (VEGF), has modest activity in myelofibrosis with myeloid metaplasia. Leukemia Research 31(7): 891-897, 2007

Anti-angiogenic and anti-tumor effects of TAK-593, a potent and selective inhibitor of VEGF and PDGF receptor tyrosine kinase. 2013

The multi-targeted kinase inhibitor SU5416 inhibits small cell lung cancer growth and angiogenesis, in part by blocking Kit-mediated VEGF expression. Lung Cancer 46(3): 283-291, 2004

Angiogenesis inhibition by the novel VEGF receptor tyrosine kinase inhibitor, PTK787/ZK222584, causes significant anti-arthritic effects in models of rheumatoid arthritis. Inflammation Research 53(4): 133-142, 2004

Anti-tumour activity of ZD6474, a VEGF receptor tyrosine kinase inhibitor. British Journal of Cancer 83(Suppl. 1): 31, 2000

NVP-AAD777/Zk202664, a selective VEGF receptor kinase inhibitor, which inhibits both VEGF- and bFGF-induced angiogenesis. Proceedings of the American Association for Cancer Research Annual Meeting 42: 940-941, 2001